» Articles » PMID: 29305710

Ecto-5'-nucleotidase/CD73 Contributes to the Radiosensitivity of T24 Human Bladder Cancer Cell Line

Abstract

Purpose: Trimodal therapy is a reasonable bladder-preserving option to radical cystectomy. However, many tumors are radioresistive. In this sense, the identification of new prognostic and predictive biomarkers that allow the selection of patients with better responses to radiation therapy would improve outcomes. With the aim of using ecto-5'-nucleotidase/CD73 as a predictive biomarker, the role of this enzyme in the context of radiotherapy in T24 human bladder cancer cell line was investigated.

Methods: T24 cell line was exposure to a single dose of radiation (4 Gray) and trypan blue assay (pharmacological assays of viability/cumulative population doubling), flow cytometry (cell cycle/cell death/active caspase-3/ecto-5'-nucleotidase/CD73 protein staining), DAPI staining (nuclear morphometric assay), RT-PCR and real-time PCR, malachite green method (ectonucleotidase enzymatic assay), and HPLC (analysis of AMP metabolism) were carried out. T24 cell line in which ecto-5'-nucleotidase/CD73 has been completely silenced (5'KO) was also used.

Results: The exposure of T24 cell line to a single dose (4 Gray) of radiation-induced cell death and triggered a transitory increase in ecto-5'-nucleotidase/CD73 expression, increased ectonucleotidase activity, and led to adenosine and inosine accumulation in the extracellular medium. Pharmacological inhibition or knocking out ecto-5'-nucleotidase/CD73 rescued cells' proliferative capacity, reducing their sensitivity to radiation.

Conclusion: Our findings show that the induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 cell line.

Citing Articles

Adenosinergic Signalling in Cervical Cancer Microenvironment.

Iser I, Bertoni A, Beckenkamp L, Consolaro M, Maria-Engler S, Wink M Expert Rev Mol Med. 2025; 27():e5.

PMID: 39762204 PMC: 11707834. DOI: 10.1017/erm.2024.30.


Zinc-Modified Titanate Nanotubes as Radiosensitizers for Glioblastoma: Enhancing Radiotherapy Efficacy and Monte Carlo Simulations.

Diz F, Monteiro W, Silveira I, Ruano D, Zotti E, Weimer R ACS Omega. 2024; 9(27):29499-29515.

PMID: 39005768 PMC: 11238320. DOI: 10.1021/acsomega.4c02125.


Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR.

Ploeg E, Samplonius D, Xiong X, Ke X, Hendriks M, Britsch I J Immunother Cancer. 2023; 11(9).

PMID: 37734877 PMC: 10514638. DOI: 10.1136/jitc-2023-006837.


A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer.

Ploeg E, Britsch I, van Wijngaarden A, Ke X, Hendriks M, Samplonius D Cancers (Basel). 2023; 15(14).

PMID: 37509310 PMC: 10378099. DOI: 10.3390/cancers15143651.


Neutrophil extracellular traps (NETs) reduce the diffusion of doxorubicin which may attenuate its ability to induce apoptosis of ovarian cancer cells.

Tamura K, Miyato H, Kanamaru R, Sadatomo A, Takahashi K, Ohzawa H Heliyon. 2022; 8(6):e09730.

PMID: 35756123 PMC: 9218137. DOI: 10.1016/j.heliyon.2022.e09730.


References
1.
Figueiro F, de Oliveira C, Bergamin L, Rockenbach L, Mendes F, Jandrey E . Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment. Purinergic Signal. 2016; 12(2):303-12. PMC: 4854832. DOI: 10.1007/s11302-016-9505-8. View

2.
Hou B, Xu Z, Yang C, Gao Y, Zhao S, Zhang C . Protective effects of inosine on mice subjected to lethal total-body ionizing irradiation. J Radiat Res. 2006; 48(1):57-62. DOI: 10.1269/jrr.06067. View

3.
Chen R, Shipley W, Efstathiou J, Zietman A . Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013; 11(8):952-60. DOI: 10.6004/jnccn.2013.0116. View

4.
Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X . Ecto-5'-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2007; 134(3):365-72. DOI: 10.1007/s00432-007-0292-z. View

5.
Wettstein M, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P . CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. Dis Markers. 2015; 2015:785461. PMC: 4620269. DOI: 10.1155/2015/785461. View